Kalehua Capital Management LLC — 13F Holdings & Portfolio

CIK 2106181 · latest 13F-HR filed 2026-11-13

Kalehua Capital Management LLC manages $132.4M in 13F-reported U.S. long-equity assets across 22 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are MANE (13.34%), BOXX (13.28%), KRSA (10.70%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 10 new positions and exited 11; 1 existing position rose in reported value and 8 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$132.4M

Long-equity book

Holdings
22

Distinct positions

Period
2026-09-30

Filed 2026-11-13

Q/Q Activity
+10 / −11 / ↑1 / ↓8

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 80.7%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Address
3819 MAPLE AVENUE
DALLAS, TX 75219
Phone
(214) 225-0846
Name Title / Status Ownership Type
CHANG, TAI-LI ControlSOLE MEMBER
since May 2022
75% or moreIndividual
Chang, Katie, Norman ControlCHIEF COMPLIANCE OFFICER
since Jan 2025
Less than 5%Individual
Ownership & leadership changes · 1 filing with changes since Feb 13, 2023

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 26, 2025 filing
  • AddedChang, Katie, Norman · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Feb 13, 2023 filing (earliest on record)
  • ListedCHANG, TAI-LI · SOLE MEMBER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Kalehua Capital Management LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 VERADERMICS INC MANE 922967104 $17.7M 13.34% 145,695 SH
2 EA SERIES TRUST BOXX 02072L565 $17.6M 13.28% 148,471 SH
3 KORSANA BIOSCIENCES INC KRSA 23255M303 $14.2M 10.70% 442,653 SH
4 X4 PHARMACEUTICALS INC XFOR 98420X202 $10.8M 8.15% 3,722,840 SH
5 ACLARIS THERAPEUTICS INC ACRS 00461U105 $9.6M 7.28% 1,832,365 SH
6 SURROZEN INC SRZN 86889P208 $9.2M 6.95% 286,092 SH
7 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $7.9M 5.93% 3,821,890 SH
8 SEPTERNA INC SEPN 81734D104 $7.6M 5.75% 194,544 SH
9 BETTERLIFE PHARMA INC BETRF 08772P202 $6.7M 5.04% 27,710,000 SH
10 OBSIDIAN THERAPEUTICS INC OBX 67448A106 $5.7M 4.32% 416,649 SH
11 INFLARX NV IFRX N44821101 $5.3M 3.97% 2,921,095 SH
12 KORRO BIO, INC KRRO 500946108 $4.7M 3.54% 473,595 SH
13 ATTOVIA THERAPEUTICS INC ATTO 04987L102 $3.4M 2.59% 200,000 SH
14 DAMORA THERAPEUTICS INC DMRA G2646Y104 $3.0M 2.23% 139,000 SH
15 UNIQURE NV QURE N90064101 $1.9M 1.45% 79,407 SH
16 GOSSAMER BIO INC GOSS 38341P201 $1.7M 1.25% 139,366 SH
17 MILESTONE PHARMACEUTICALS IN MIST 59935V107 $1.4M 1.08% 1,651,258 SH
18 LEONABIO INC LONA 04746L203 $1.4M 1.06% 393,701 SH
19 ATRIUM THERAPEUTICS INC RNA 04965N104 $932.8K 0.70% 112,652 SH
20 INSTIL BIO INC TIL 45783C200 $721.1K 0.54% 99,600 SH
21 ATYR PHARMA INC ATYR 002120202 $554.3K 0.42% 1,829,513 SH
22 KAZIA THERAPEUTICS LTD KZIA 48669G303 $537.4K 0.41% 56,013 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-13 $132.4M 22 0002106181-26-000010
2026-06-30 2026-08-19 $174.0M 26 0002106181-26-000008
2026-06-30 2026-08-14 $139.5M 23 0002106181-26-000007
2026-03-31 2026-05-15 $141.3M 27 0002106181-26-000005
2026-03-31 2026-05-15 $118.6M 23 0002106181-26-000004
2025-12-31 2026-02-13 $101.1M 19 0002106181-26-000003
Filer Information
Address
3819 MAPLE AVENUE
DALLAS, TX 75219
Phone
(214) 225-0846
Filing Manager
Kalehua Capital Management LLC
DALLAS, TX
Signatory
Tai-Li Chang
Managing Director